Orion Oyj : Orion and Mylan settle patent dispute over the proprietary drug Stalevo®

 Orion Oyj : Orion and Mylan settle patent dispute over the proprietary drug
                                   Stalevo®

ORION CORPORATION    STOCK EXCHANGE RELEASE25 JULY 2013 at 11.25
a.m.EEST       

Orion Corporation ("Orion") and Mylan Pharmaceuticals Inc. ("Mylan") have
executed a settlement and license agreement to settle the lawsuit filed by
Orion in the United States against Mylan regarding Mylan's submission of an
abbreviated new drug application ("ANDA") for generic versions of Orion's
Stalevo® (carbidopa/levodopa/entacapone) product.

The lawsuit was filed by Orion in the U.S. in April 2012. Under the terms of
the settlement and license agreement, Mylan shall be authorized to launch
generic versions of the Stalevo product (strengths 12.5/50/200 mg;
18.75/75/200 mg; 25/100/200 mg; 31.25/125/200 mg; 37.5/150/200 mg and
50/200/200 mg) immediately after entry of the agreement.

Subject to the Court's approval, the lawsuit against Mylan will be dismissed
and the U.S. Patents Nos. 5,446,194, 6,500,867 and 6,797,732 shall remain in
force.

In compliance with the applicable U.S. laws, Orion will file the above
agreement with the United States Federal Trade Commission and the United
States Department of Justice.


Orion Corporation

Timo Lappalainen  Olli Huotari
President and CEO SVP, Corporate Functions

           

Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. Pharmaceutical R&D focuses on central nervous
system drugs, oncology and critical care drugs, and Easyhaler® pulmonary
drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX
Helsinki.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Orion Oyj via Thomson Reuters ONE
HUG#1717831
 
Press spacebar to pause and continue. Press esc to stop.